SCYNEXIS, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SCYX Nasdaq 2830 www.scynexis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SCYNEXIS, Inc.

Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested - Jun 1st, 2026 12:14 am
SCYNEXIS Announces One-for-Eight Reverse Stock Split - May 22nd, 2026 2:15 pm
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 11th, 2026 2:23 pm
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 6th, 2026 7:15 pm
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease - Mar 31st, 2026 5:59 am
SCYNEXIS Announces $40.0 Million Private Placement - Mar 31st, 2026 4:45 am
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Mar 31st, 2026 4:40 am
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy - Mar 12th, 2026 1:38 am
Scynexis: Q4 Earnings Snapshot - Mar 4th, 2026 3:36 pm
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - Mar 4th, 2026 2:20 pm
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - Feb 26th, 2026 6:23 am
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - Feb 17th, 2026 6:00 am
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) - Jan 28th, 2026 6:00 am
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 - Jan 21st, 2026 6:00 am
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Dec 22nd, 2025 6:00 am
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - Nov 19th, 2025 5:00 am
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections - Nov 17th, 2025 8:15 am
Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation - Nov 10th, 2025 4:58 am
Scynexis: Q3 Earnings Snapshot - Nov 5th, 2025 2:51 pm
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 5th, 2025 2:20 pm